Betaxolol 5 MG/ML Ophthalmic Solution — RxCUI 308720
RxNorm drug concept · Semantic clinical drug
RxCUI 308720
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI308720
Official nameBetaxolol 5 MG/ML Ophthalmic Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbetaxolol 0.5 % Ophthalmic Solution; betaxolol HCl 0.5 % Ophthalmic Solution; betaxolol 5 MG/ML (betaxolol hydrochloride 5.6 MG/ML) Ophthalmic Solution
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)737 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Betaxolol: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- That's a really common concern, and it's a good one to ask. The eye drops are absorbed into the bloodstream to some extent, but betaxolol is specifically designed to target the eye...
- I'm getting the eye drops for glaucoma — will they affect my heart or lungs like a regular beta-blocker pill would?
- Please don't stop them on your own, especially not abruptly. With betaxolol tablets, stopping suddenly — particularly if you have any coronary artery disease — can cause a rebound...
- Can I just stop taking my betaxolol tablets if I feel fine and my blood pressure seems okay?
🕸️ Concept Web — How Betaxolol 5 MG/ML Ophthalmic Solution Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Betaxolol 5 MG/ML Ophthalmic Solution
RxCUI 308720 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Betaxolol
1520IN
-
Betaxolol
-
Dose forms 4
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Betaxolol Ophthalmic Solution
377437SCDF -
Betaxolol Ophthalmic Product
1153806SCDG -
Ophthalmic Solution
7670DF -
Ophthalmic Product
1151135DFG
-
Betaxolol Ophthalmic Solution
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Betaxolol 5 MG/ML
329587SCDC
-
Betaxolol 5 MG/ML
Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Betaxolol 5 MG/ML
SCDC · 329587 -
Betaxolol Ophthalmic Solution
SCDF · 377437 -
Betaxolol Ophthalmic Product
SCDG · 1153806
📦 FDA Products & Package NDCs
1 product · 3 package NDCs
3 package NDCs map to RxCUI 308720 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 61314-0245-01 | 1 BOTTLE, PLASTIC in 1 CARTON (61314-245-01) / 5 mL in 1 BO... | Betaxolol Hydrochloride | Sandoz Inc | 2000-05-15 |
| 61314-0245-02 | 1 BOTTLE, PLASTIC in 1 CARTON (61314-245-02) / 15 mL in 1 B... | Betaxolol Hydrochloride | Sandoz Inc | 2000-05-15 |
| 61314-0245-03 | 1 BOTTLE, PLASTIC in 1 CARTON (61314-245-03) / 10 mL in 1 B... | Betaxolol Hydrochloride | Sandoz Inc | 2000-05-15 |
Observed labelers:
Sandoz Inc (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$8.7127
Range $8.6864–$8.7390
· middle 50% $8.6996–$8.7259
· 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.